# Safety and Efficacy of Berodual® Inhaled Via Respimat® Compared to MDI (Metered Dose Inhaler) in Pediatric Patients With Asthma

> **NCT02182505** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 535 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Berodual® Respimat®, low dose
- **DRUG:** Berodual® Respimat®, high dose
- **DRUG:** Berodual® MDI

## Key facts

- **NCT ID:** NCT02182505
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-09
- **Primary completion:** 1999-07
- **Final completion:** —
- **Target enrollment:** 535 (ACTUAL)
- **Last updated:** 2014-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02182505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02182505, "Safety and Efficacy of Berodual® Inhaled Via Respimat® Compared to MDI (Metered Dose Inhaler) in Pediatric Patients With Asthma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02182505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*